NeoTherapeutics Incorporated

NeoTherapeutics Incorporated is a development stage biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs intended to treat neurodegenerative diseases and conditions, such as memory deficits associated with Alzheimer's disease and aging, stroke, spinal cord injuries, Parkinson's disease, migraine, depression and obesity. The Company's initial product candidate, NEOTROFIN(TM) (AIT-082, leteprinim potassium) and other compounds under development are based on the Company's patented technology. This technology uses small synthetic molecules to create non-toxic compounds, intended to be administered orally or by injection, that are capable of passing through the blood-brain barrier to rapidly act upon specific target cells in specific locations in the central nervous system, including the brain.

Contact Details: 157 Technology DriveSuite J-821 Irvine CA 92618 United States of America Tel: 949 788 6700 Fax: 949 788-6706 Email: info@neotherapeutics.com WWW: www.neotherapeutics.com/

Loading...

Recent Publications by NeoTherapeutics Incorporated:
Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones. RATIONALE: AIT-082 (Neotrofin), a hypoxanthine derivative, has been shown...	25th July, 2003	NeoTherapeutics Inc, 157 Technology Drive, Irvine, CA 92618, USA.	Psychopharmacology (Berl). 2003 Apr;166(4):400-7. Epub 2003 Feb 26. DOI Direct Link
Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity. Dexmedetomidine is a highly specific alpha2-adrenergic agonist, which is...	1st August, 2000	NeoTherapeutics, Irvine, California, USA.	J Cereb Blood Flow Metab. 2000 Jun;20(6):895-8. DOI Direct Link
AIT-082, a cognitive enhancer, is transported into brain by a nonsaturable influx mechanism and out of brain by a saturable efflux mechanism. A fundamental feature of any drug designed to treat a disease of the...	25th July, 2000	NeoTherapeutics	J Pharmacol Exp Ther. 2000 Jun;293(3):813-21.

NeoTherapeutics Incorporated Clinical Trials:
Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NeoTherapeutics Incorporated Patents:
US Patent No.	Title
6630490	Methods for treatment of disease-induced peripheral neuropathy and related conditions
6630478	Methods for treatment of drug-induced peripheral neuropathy
6407237	Crystal forms of 9-substituted hypoxanthine derivatives
6338963	Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
6303617	Serotonin-like 9-substituted hypoxanthine and methods of use
→View more NeoTherapeutics Incorporated patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 450 times since April 2007, the link to the organisation's website has been followed 113 times

Search for more companies in Irvine

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for NeoTherapeutics Incorporated